Yohann Loriot explored rechallenge with the same class of agents in advanced urothelial and renal cell carcinomas ... A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

Spirulina has solid potential as a therapeutic adjuvant, according to researchers in Australia who isolated extracellular vesicles (EVs)—nanoscale vesicles enclosed with bilayer phospholipid ...

University of Sheffield experts said the drug durvalumab could reduce the recurrence of operable bladder cancer by a third Medical experts in Sheffield have hailed as a "game changer" trials of a ...

bDepartments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA cClinical and Translational Epidemiology Unit and Division of Gastroenterology, ...

Results showed that overall survival at two years reached 82.2 per cent in patients receiving Durvalumab, compared to 75.2 per cent in those who did not. The final-stage phase three clinical trial ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more ...

Half of the participants were given the standard treatment of chemotherapy and surgery, while the other half were given durvalumab, also known by brand name Imfinzi, in addition. The proportion of ...